The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 08, 2025
Filed:
Mar. 03, 2021
Cov-2 (cov-n) antibody neutralizing and ctl vaccines using protein scaffolds and molecular evolution
Applicant:
Swey-shen Chen, San Diego, CA (US);
Inventor:
Swey-Shen Chen, San Diego, CA (US);
Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/215 (2006.01); C07K 14/005 (2006.01); C07K 14/73 (2006.01); C12N 7/00 (2006.01); C12Q 1/02 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/005 (2013.01); A61K 39/215 (2013.01); C07K 14/70514 (2013.01); C12N 7/00 (2013.01); A61K 2039/53 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20034 (2013.01);
Abstract
The embodiment of the invention is to conformationally constrain neutralizing B cell epitopes of CoV-2, CoV-n B cell epitopes of the open reading frame proteins, including the membrane S protein, constrained by protein scaffolds, including camelid VHH nanobody in order to elicit neutralizing and blocking antibodies against viral infection. B cell epitopes are molecularly evolved by ribosome display to preempt emerging viral B cell epitopes. Moreover, CTL epitopes are designed from the open reading frame protein for eliciting cell mediated viral protection. Furthermore, mRNA vaccines are prepared for eliciting protective immunity and prevent cytokine storms.